Novan Announces Full Top Line Results from Phase 2 Molluscum Contagiosum Clinical Trial and Decision to Move Forward with SB206 12% Once-Daily
December 10, 2018 07:30 ET
|
Novan, Inc.
SB206 12% once-daily achieved the highest rate of complete clearance out of all active treatment groups at Week 12 (p<0.05)Statistically significant reductions in molluscum lesions as early as Week...
Novan Phase 2 Molluscum Contagiosum Trial Achieves Statistical Significance in Preliminary Top Line Results
November 14, 2018 06:30 ET
|
Novan, Inc.
Higher rates of complete clearance of all molluscum lesions at Week 12 for the two highest doses, SB206 8% and 12% twice-daily, more than double the rate observed in the vehicle groupClear treatment...
Novan Publication Supports Women’s Health Business Unit Initiative and Nitric Oxide’s Potential Against HPV-Associated Diseases
November 01, 2018 08:05 ET
|
Novan, Inc.
Data from SB206 Phase 2 clinical trial in external genital warts have been published in the Journal of Drugs in DermatologySB206 was efficacious and well tolerated in the trialAdvancement of the late...
Novan Creates Dedicated Women’s Health Business Unit
October 25, 2018 07:05 ET
|
Novan, Inc.
Business unit will focus on Novan’s proprietary nitric oxide technology and its application to target high-risk human papillomavirus (HPV) and associated cancers affecting women such as cervical...
Novan Expands Nitric Oxide Dermatology Business Partnership with Sato in Japan
October 08, 2018 08:00 ET
|
Novan, Inc.
Expanded license agreement adds SB206 for the treatment of viral skin infections Novan to receive upfront cash consideration of approximately 1.25 billion JPY (~$11.0 million), payable over the next...
Novan’s Phase 2 Molluscum Contagiosum Trial Fully Enrolled: Top Line Results Targeted in November
October 01, 2018 08:05 ET
|
Novan, Inc.
Trial enrollment completed meaningfully ahead of scheduleTop line results targeted to be communicated no later than mid-NovemberFavorable and consistent safety profile of SB206 enabled escalation to...
Novan Announces First Patient Dosed in Phase 2 Molluscum Contagiosum Trial with SB206
January 25, 2018 09:00 ET
|
Novan, Inc.
MORRISVILLE, N.C., Jan. 25, 2018 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (NASDAQ:NOVN) today announced that the first patient has been dosed in the Company's Phase 2 clinical...
Novan Acquires IP Rights to Treat Viral Malignancies with Nitric Oxide
October 18, 2017 07:05 ET
|
Novan, Inc.
Expanded Indications in Field of Virology Build on SB206 Clinical Success Against Human Papillomavirus Company Doses First Patient in Inflammatory Skin Disease Program in Phase 1b Psoriasis Trial...
Novan’s Phase 2 Results with SB206 to be Presented at 2017 AAD Annual Meeting
March 02, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that data from the Company’s Phase 2 clinical trial with SB206 for the...
Novan Announces Presentation of Anti-Viral Data at International Papillomavirus Conference
March 01, 2017 09:05 ET
|
Novan, Inc.
MORRISVILLE, N.C., March 01, 2017 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (NASDAQ:NOVN) today announced that preclinical data demonstrating the anti-viral effects of the Company’s...